Krystal Biotech has made a strategic decision to halt a Phase I/II study of its experimental intratumoral therapy KB707, primarily targeted at treating solid tumors like melanoma. This move by the Pennsylvania-based biotech comes in the wake of the FDA’s recent rejection of Replimune’s RP1, a similar treatment approach to KB707. The rejection of RP1 has injected a level of uncertainty into the accelerated approval pathway for KB707, prompting Krystal Biotech to reevaluate its development plans for the therapy.
Both KB707 and RP1 are classified as immunotherapies utilizing modified herpes simplex virus type 1 vectors to stimulate an immune response against tumors, particularly in melanoma cases. Krystal Biotech’s suspension of enrollment in the Phase I/II OPAL-1 study does not signify the end of the road for KB707; the company will continue monitoring the safety and efficacy of patients already under treatment. Depending on the trial outcomes, Krystal may pivot its development strategies for intratumoral KB707 based on the evolving landscape influenced by the FDA’s actions.
The rejection of RP1 by the FDA stirred controversy within the scientific and biotech community. The decision to overrule agency reviewers and decline RP1 was championed by Richard Pazdur, a key figure at the FDA’s Oncology Center of Excellence. However, subsequent calls from experts and scientists involved in Replimune’s Phase III trial urged the FDA to reconsider its stance. These professionals highlighted critical aspects of the trial design and patient population heterogeneity that they believed provided a more realistic representation of the treatment’s efficacy in real-world scenarios.
As Krystal Biotech redirects its focus away from intratumoral KB707, the company is channeling efforts into an inhaled form of the drug tailored for non-small cell lung cancer (NSCLC) treatment. Encouraging results from early efficacy assessments prompted the FDA to grant an End of Phase II meeting to discuss the next steps for the inhaled KB707. Data from June revealed a notable objective response rate of 36% in heavily treated NSCLC patients, with promising outcomes in terms of response duration and progression-free survival, coupled with a favorable safety profile devoid of severe adverse events.
Looking ahead, Krystal’s regulatory meeting in October will play a pivotal role in charting the trajectory for advancing inhaled KB707 through potential approval pathways. This shift in focus underscores the dynamic nature of biotech development, where strategic pivots are often necessary in response to regulatory uncertainties and evolving clinical data. Krystal Biotech’s adaptive approach reflects the resilience and agility required in navigating the intricate landscape of drug development and regulatory pathways.
Key Takeaways:
– FDA’s rejection of RP1 has introduced uncertainty in the accelerated approval pathway for KB707, prompting Krystal Biotech to reassess its development plans.
– Scientific community pushback against FDA decisions highlights the nuanced considerations involved in regulatory approvals for novel therapies.
– Krystal’s transition to an inhaled version of KB707 for NSCLC treatment showcases the agility and adaptability crucial in biotech development amidst regulatory challenges.
– Early efficacy data for inhaled KB707 in NSCLC patients has been promising, setting the stage for potential advancements in the drug’s development pathway.
Tags: immunotherapy, regulatory, biotech
Read more on biospace.com